Kathryn E. Beckermann, MD, PhD, discusses the future of treatment in renal cell carcinoma.
Kathryn E. Beckermann, MD, PhD, assistant professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, discusses the future of treatment in renal cell carcinoma (RCC).
Data reported in RCC over the past year have supported some of the current frontline treatment options in the standard of care, Beckermann says. Since the current frontline treatment landscape has not been challenged by recent data, those in the industry and at institutions need to explore novel ideas to develop improved therapies, Beckermann explains.
These continued efforts across RCC will help define new biomarkers that could lead to more tailored treatments or the ability to monitor response in a noninvasive way, Beckermann concludes.